Looks like you’re on the UK site. Choose another location to see content specific to your location

Home Industry News GSK unit advances ofatumumab into phase III trials

GSK unit advances ofatumumab into phase III trials

9th October 2014

GlaxoSmithKline (GSK) has announced its dermatology unit Stiefel is to begin phase III trials of its ofatumumab treatment, which is designed for use in patients suffering from a life-threatening autoimmune skin condition.

The trial comprises patients diagnosed with pemphigus vulgaris – a rare but serious condition that causes those afflicted to develop painful blisters in the mouth and on the skin, which can become infected easily. In some severe cases, these infections have become systemic and lead to organ failure and death. 

Currently, the typical treatment for the disease – thought to affect around seven million people globally – is very large doses of systemic corticosteroids, though these have serious and potentially life-threatening side-effects.

Stiefel's year-long trial will test a new subcutaneous formulation of ofatumumab, which after an initial loading dose, will be given once per month. 

An intravenous formulation of the drug has been sold under the Arzerra name as a treatment for chronic lymphocytic leukemia since 2009, but this was one of several cancer drugs transferred from GSK to Novartis under the asset-swap deal announced earlier this year.ADNFCR-8000103-ID-801753432-ADNFCR

We currently have 9 jobs available in Pharmacy industry, find your perfect one now.

Stay informed

Receive the latest industry news, Tips
and straight to your inbox.